Management of Hair Loss

The document from 2005 provides an overview of treatments for hair loss, including male and female pattern hair loss (MPHL and FPHL), telogen effluvium, and alopecia areata (AA). For MPHL, 5% minoxidil and oral finasteride are FDA-approved, with 57% of men experiencing regrowth after 48 weeks on minoxidil and 66% after 2 years on finasteride. Combination therapy may be more effective. For FPHL, 2% minoxidil is FDA-approved, with 63% of women showing regrowth in a 32-week study. Non-approved treatments include antiandrogens with variable effectiveness. For AA, treatments like corticosteroids, topical immunotherapy, and minoxidil are used, with a foam formulation of corticosteroids showing 61% of patients achieving significant regrowth at 8 weeks. The document emphasizes the need for individualized treatment plans and acknowledges the complexity of managing hair loss.